OR Royalties (NYSE:OR) Upgraded to “Strong-Buy” at Wall Street Zen

Wall Street Zen upgraded shares of OR Royalties (NYSE:OR) from a buy rating to a strong-buy rating in a research note issued to investors on Saturday.

Several other analysts have also recently issued reports on OR. Canadian Imperial Bank of Commerce reiterated an “outperform” rating on shares of OR Royalties in a research note on Wednesday, February 4th. Zacks Research upgraded OR Royalties from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 4th. Weiss Ratings reiterated a “buy (b)” rating on shares of OR Royalties in a research note on Monday, December 29th. Scotiabank boosted their target price on OR Royalties from $41.00 to $51.00 and gave the company a “sector perform” rating in a report on Monday, January 26th. Finally, Jefferies Financial Group reiterated a “hold” rating and set a $38.00 price target on shares of OR Royalties in a research note on Sunday, December 7th. Two investment analysts have rated the stock with a Strong Buy rating, five have assigned a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $38.25.

OR Royalties Trading Down 4.9%

OR Royalties stock opened at $32.89 on Friday. The stock has a market cap of $6.17 billion, a P/E ratio of 30.17 and a beta of 0.75. The company has a 50-day moving average price of $42.40 and a 200 day moving average price of $37.88. OR Royalties has a 12-month low of $18.99 and a 12-month high of $48.06.

OR Royalties (NYSE:OR) last posted its earnings results on Wednesday, February 18th. The basic materials company reported $0.32 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.01. OR Royalties had a return on equity of 12.73% and a net margin of 74.30%.The company had revenue of $90.47 million for the quarter, compared to the consensus estimate of $90.80 million. As a group, analysts forecast that OR Royalties will post 0.62 EPS for the current year.

OR Royalties Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Tuesday, March 31st will be issued a $0.055 dividend. This represents a $0.22 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Tuesday, March 31st. OR Royalties’s dividend payout ratio is 20.18%.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Linden Thomas Advisory Services LLC grew its stake in shares of OR Royalties by 4.1% during the 4th quarter. Linden Thomas Advisory Services LLC now owns 6,254 shares of the basic materials company’s stock valued at $221,000 after buying an additional 249 shares during the period. Wells Fargo & Company MN lifted its holdings in shares of OR Royalties by 6.2% during the 4th quarter. Wells Fargo & Company MN now owns 5,901 shares of the basic materials company’s stock valued at $209,000 after acquiring an additional 346 shares in the last quarter. Allworth Financial LP boosted its position in shares of OR Royalties by 20.0% in the fourth quarter. Allworth Financial LP now owns 2,305 shares of the basic materials company’s stock worth $82,000 after buying an additional 384 shares during the period. Cetera Investment Advisers lifted its position in OR Royalties by 3.5% during the 2nd quarter. Cetera Investment Advisers now owns 13,147 shares of the basic materials company’s stock worth $337,000 after acquiring an additional 440 shares in the last quarter. Finally, FIL Ltd acquired a new stake in OR Royalties in the fourth quarter valued at approximately $29,000. Hedge funds and other institutional investors own 68.52% of the company’s stock.

About OR Royalties

OR Royalties PLC (NYSE: OR) is a closed-ended investment company that specializes in acquiring and managing royalty interests in life science and pharmaceutical products. The company provides capital to biotechnology, specialty pharmaceutical and medical device companies in exchange for a share of future sales revenues. By focusing on royalties secured against marketed products, OR Royalties aims to deliver income and growth potential while minimizing the development and commercialization risks typically associated with direct equity stakes.

The company’s core activities include sourcing royalty transactions, structuring bespoke financing solutions and actively monitoring a diversified portfolio of assets.